165 related articles for article (PubMed ID: 20063032)
1. Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome.
Haaland K
J Headache Pain; 2010 Apr; 11(2):167-9. PubMed ID: 20063032
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Gales BJ; Bailey EK; Reed AN; Gales MA
Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
4. Teratogenicity with angiotensin II receptor antagonists in pregnancy.
Boix E; Zapater P; Picó A; Moreno O
J Endocrinol Invest; 2005 Dec; 28(11):1029-31. PubMed ID: 16483184
[TBL] [Abstract][Full Text] [Related]
5. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Bald M; Holder M; Zieger M; Vochem M; Leichter HE
Pediatr Nephrol; 2005 Nov; 20(11):1664-5, 1666-8. PubMed ID: 16082550
[No Abstract] [Full Text] [Related]
6. [Cross reactivity between ACE inhibitors and angiotensin receptor blockers].
Rosenborg S
Lakartidningen; 2010 Feb 17-23; 107(7):444. PubMed ID: 20384078
[No Abstract] [Full Text] [Related]
7. Angiotensin II receptor blocker induced fetopathy: 7 cases.
Hünseler C; Paneitz A; Friedrich D; Lindner U; Oberthuer A; Körber F; Schmitt K; Welzing L; Müller A; Herkenrath P; Hoppe B; Gortner L; Roth B; Kattner E; Schaible T
Klin Padiatr; 2011 Jan; 223(1):10-4. PubMed ID: 21271514
[TBL] [Abstract][Full Text] [Related]
8. Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.
Sinelli MT; Cattarelli D; Cortinovis S; Maroccolo D; Chirico G
Pediatr Med Chir; 2008; 30(6):306-8. PubMed ID: 19431954
[TBL] [Abstract][Full Text] [Related]
9. Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.
Kato K; Okuda M; Ishikawa H; Takahashi T; Hirahara F
J Obstet Gynaecol Res; 2008 Apr; 34(2):242-6. PubMed ID: 18412789
[TBL] [Abstract][Full Text] [Related]
10. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
Hennekens CH; Kowalczykowski M; Hollar D
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
[TBL] [Abstract][Full Text] [Related]
11. Migraine prophylaxis with drugs influencing the renin-angiotensin system.
Stovner LJ
Eur J Neurol; 2007 Jul; 14(7):713-4. PubMed ID: 17594324
[No Abstract] [Full Text] [Related]
12. [Fetal toxicity of angiotensin-II receptor antagonists].
Payen V; Chemin A; Jonville-Béra AP; Saliba E; Cantagrel S
J Gynecol Obstet Biol Reprod (Paris); 2006 Nov; 35(7):729-31. PubMed ID: 17088776
[TBL] [Abstract][Full Text] [Related]
13. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
14. [Angiotensin receptor blockers in heart failure. CHARM Study].
Kochsiek K
Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
[No Abstract] [Full Text] [Related]
15. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy.
Cox RM; Anderson JM; Cox P
BJOG; 2003 Nov; 110(11):1038. PubMed ID: 14592593
[No Abstract] [Full Text] [Related]
16. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
Enzensberger C; Eskef K; Schwarze A; Faas D; Axt-Fliedner R
Ultraschall Med; 2012 Oct; 33(5):493-6. PubMed ID: 21630188
[No Abstract] [Full Text] [Related]
17. [Angiotensin II antagonist treatment as a contributory cause of acute renal failure].
Nielsen LR
Ugeskr Laeger; 2003 Mar; 165(13):1368-9. PubMed ID: 12703286
[TBL] [Abstract][Full Text] [Related]
18. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
19. Noncholestatic acute hepatocellular injury following candesartan administration.
Lammel-Lindemann JA; Flores-Villalba E; Martagón AJ; DeObeso-Gonzalez E; Puente-Gallegos F
Br J Clin Pharmacol; 2018 Jan; 84(1):204-207. PubMed ID: 28841231
[TBL] [Abstract][Full Text] [Related]
20. [Candesartan-induced cholestatic hepatitis: a case report].
Jiménez-Sáenz M; Arroyo Q; Sanjuan M; Herrerías JM
Gastroenterol Hepatol; 2010 Jan; 33(1):66-7. PubMed ID: 19713003
[No Abstract] [Full Text] [Related]
[Next] [New Search]
